Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.77 USD | +0.36% | +6.95% | -12.89% |
Mar. 07 | Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 07 | Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024 |
Financials (USD)
Sales 2024 * | 10.51M | Sales 2025 * | 10.3M | Capitalization | 22.4M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -39M | EV / Sales 2024 * | 2.13 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.18 x |
P/E ratio 2024 * |
-0.99
x | P/E ratio 2025 * |
-1.45
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.98% |
Latest transcript on Lumos Pharma, Inc.
1 day | +0.36% | ||
1 week | +6.95% | ||
Current month | -1.77% | ||
1 month | -3.82% | ||
3 months | -3.65% | ||
6 months | -23.69% | ||
Current year | -12.89% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.77 | +0.36% | 688 |
24-04-25 | 2.76 | -1.25% | 1,569 |
24-04-24 | 2.795 | -0.18% | 46,348 |
24-04-23 | 2.8 | +4.48% | 17,131 |
24-04-22 | 2.68 | +3.47% | 4,652 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.89% | 22.4M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- LUMO Stock